Reply to Olle et al. - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Reply to Olle et al.

  • By

  • Brendan J Kelly

  • Jennie H Kwon

  • Michael H Woodworth

  • November 19, 2024

Share

Objective:

To clarify the distinction between 'fecal microbiota product' and 'live biotherapeutic product' in microbiome-based therapeutics.

Key Findings:
  • Clear terminology helps clinicians distinguish between treatment modalities.
  • Fecal microbiota products and live biotherapeutic products may enhance treatment for Clostridioides difficile infection and multidrug-resistant infections.
Interpretation:

The distinction in terminology is crucial for effective communication and treatment strategies in microbiome therapies.

Limitations:
Conclusion:

Both fecal microbiota products and live biotherapeutic products are expected to remain valuable for treating infections and advancing scientific understanding.

Original Source(s)

Reply to Olle et al.

  • by Brendan J Kelly, Jennie H Kwon, Michael H Woodworth

  • November 19, 2024

Related Content

Microsporidial keratoconjunctivitis may mimic allergy

Molecular testing identified Encephalitozoon hellem in a 9-year-old orthokeratology lens wearer after conventional treatment failed.

Oral Microbiome Richness Tied to CRS

A cross-sectional metagenomic study found greater oral microbiome richness among adults with chronic rhinosinusitis, particularly nonallergic chronic rhinosinusitis, while associations with asthma, airway inflammation, and most lung-function measures were inconsistent.

How does IBD relate to joint infection risk?

Investigators assessed 90-day outcomes among patients with IBD who underwent elective total joint arthroplasty.